ADC stands for Antibody-Drug Conjugate, which is a type of targeted therapy used in the treatment of cancer. An ADC consists of a monoclonal antibody, which is a type of protein that specifically recognizes and binds to cancer cells, and a cytotoxic drug, which is a chemical that is toxic to cells. The antibody and drug are linked together through a chemical process called bioconjugation. Bioconjugation refers to the process of chemically linking two biological molecules, such as proteins and small molecules, to form a conjugate. This allows the targeted delivery of drugs to specific cells or tissues, increasing their effectiveness and reducing side effects. In the case of ADC, the bioconjugation allows the cytotoxic drug to be delivered specifically to cancer cells, where it can cause damage and lead to cell death. ADC and bioconjugation are important tools in the fight against cancer, offering a way to deliver therapeutic agents directly to the site of disease, improving outcomes and reducing side effects for patients.
